Hem › Äggstockscancer › Massachusetts › Boston
Kliniska studier för Äggstockscancer i Boston, MA
61 studier för Äggstockscancer söker deltagare vid platser i och runt Boston (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RekryterarFas 1/2
- Research Site, Boston
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekryterarFas 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RekryterarFas 1/2
- Research Site, Boston
A Study of PHST001 in Advanced Solid Tumors
RekryterarFas 1
- Dana Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekryterarFas 1
- Massachusetts General Hospital, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekryterarFas 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RekryterarFas 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Rekryterar
- Dana-Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekryterarFas 1
- Dana Farber Cancer Institute, Boston
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Rekryterar
- Dana Farber Cancer Institute, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RekryterarFas 1
- Research Site, Boston
- Research Site, Boston
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RekryterarFas 2
- Site 0221 - Tufts Medical Center - PPDS, Boston
- Site 0104 - Dana Farber Cancer Institute, Boston
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RekryterarFas 1/2
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RekryterarFas 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekryterarFas 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekryterarFas 1/2
- Dana Farber Cancer Institute, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekryterarFas 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RekryterarFas 1/2
- Massachusetts General Hospital, Boston
Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
RekryterarFas 2
- Tufts Medical Center, Boston
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekryterarFas 2
- Massachusetts General Hospital, Boston
A Study of Isoquercetin in People With Ovarian Cancer
RekryterarFas 2
- Beth Israel Deaconess Medical Center (Data Collection Only), Boston
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
RekryterarFas 2
- Massachusetts General Hospital, Boston
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RekryterarFas 1/2
- Tufts, Boston
- Dana-Farber Cancer Institute, Boston
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
RekryterarFas 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RekryterarFas 1/2
- Research Site, Boston
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
RekryterarFas 1
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekryterarFas 1
- Dana Farber Cancer Institute, Boston
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
RekryterarFas 1
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekryterarFas 1/2
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RekryterarFas 1
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekryterarFas 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Rekryterar
- Beth Israel Deaconess Medical Center, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekryterarFas 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RekryterarFas 2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
RekryterarFas 1
- Beth Israel Deaconess Medical Center, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
RekryterarFas 1
- Massachusetts General Hospital, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekryterarFas 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- och 2 fler
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RekryterarFas 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekryterarFas 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
RekryterarFas 2
- GSK Investigational Site, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
Rekryterar
- Dana-Farber Cancer Institute, Boston
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
RekryterarFas 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
RekryterarFas 1
- Dana Farber Cancer Institute, Boston
Video Education With Result Dependent dIsclosure
Rekryterar
- Dana Farber Cancer Institute, Boston
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
RekryterarFas 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RekryterarFas 1/2
- Massachusetts General Hospital, Boston
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Rekryterar
- Massachusetts General Hospital-Cancer Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
RekryterarFas 1
- Site 0104, Boston
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Rekryterar
- Dana Farber Cancer Institute, Boston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
RekryterarFas 1/2
- Dana-Farber Cancer Institute, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RekryterarFas 1/2
- Massachusetts General Hospital, Boston
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Rekryterar
- Dana Farber Cancer Institute, Boston
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RekryterarFas 1
- Massachusetts General Hospital, Boston
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
RekryterarFas 1
- Dana Farber Cancer Institute, Boston
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RekryterarFas 2
- Massachusetts General Hospital, Boston
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RekryterarFas 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RekryterarFas 1/2
- Dana Farber Cancer Institute, Boston
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
RekryterarObservationsstudie
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
RekryterarFriska volontärer välkomna
- Dana Farber Cancer Institute, Boston
Äggstockscancer-studier i andra städer
- Houston, TX89 studier
- New York City, NY69 studier
- Los Angeles, CA50 studier
- Nashville, TN49 studier
- Arlington, VA46 studier
- Philadelphia, PA44 studier
- Columbus, OH39 studier
- St. Louis, MO38 studier
- Chicago, IL36 studier
- San Antonio, TX31 studier
- Cleveland, OH30 studier
- Pittsburgh, PA30 studier
Andra studier i Boston
- Bröstcancer112 studier
- Icke-småcellig lungcancer90 studier
- Cancer (alla typer)85 studier
- Metastaserande cancer63 studier
- Kolorektal cancer63 studier
- Lungcancer62 studier
- Prostatacancer59 studier
- Depression52 studier
- Endometriecancer50 studier
- Hjärtsvikt44 studier
- Akut myeloid leukemi44 studier
- Bukspottkörtelcancer43 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.